Free Trial

Moderna (MRNA) Earnings Date, Estimates & Call Transcripts

Moderna logo
$36.85 -2.92 (-7.34%)
(As of 11/15/2024 ET)

Moderna Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 27Estimated
Actual EPS
(Nov. 7)
$0.03 Beat By $1.92
Consensus EPS
(Nov. 7)
-$1.89

Moderna posted Q3 2024 earnings on November 7, 2024, reporting an EPS of $0.03, which topped analysts' consensus estimates of -$1.89 by $1.92. Quarterly revenue rose 3.8% year-over-year to $1.90 billion, above the consensus estimate of $1.25 billion. With a trailing EPS of -$5.82, Moderna's earnings are expected to grow next year, from ($9.43) to ($8.69) per share.

MRNA Upcoming Earnings

Moderna's next earnings date is estimated for Thursday, February 27, 2025, based off prior year's reporting schedules.

Get Moderna Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Moderna and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

MRNA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

MRNA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Moderna Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20244-$3.49-$1.86-$2.66
Q2 20244-$3.47-$1.85-$3.02
Q3 20244-$1.88$0.10-$0.97
Q4 20244-$1.83$1.60-$0.38
FY 202416-$10.67-$2.01-$7.02
Q1 20251-$2.90-$2.90-$2.90
Q2 20251-$3.11-$3.11-$3.11
Q3 20252-$1.44$1.30-$0.07
Q4 20252-$1.25$1.36$0.06
FY 20256-$8.70-$3.35-$6.03
Q1 20261-$2.68-$2.68-$2.68
Q2 20261-$2.76-$2.76-$2.76
Q3 20261-$0.72-$0.72-$0.72

Moderna Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/27/2025
(Estimated)
------- 
11/7/2024Q3 2024-$1.89$0.03+$1.92$0.03$1.25B$1.90B        
8/1/2024Q2 2024-$3.47-$3.33+$0.14-$3.33$128.41M$241.00M        
5/2/2024Q1 2024-$3.59-$3.07+$0.52-$3.07$93.26M$167.00M        
2/22/2024Q4 2023-$0.78$0.55+$1.33$0.55$2.53B$2.80B        
11/2/2023Q3 2023-$2.01-$1.39+$0.62$6.75$1.37B$1.83B    
8/3/2023Q2 2023-$3.84-$3.62+$0.22-$3.62$307.67M$344.00M        
5/4/2023Q1 2023-$1.77$0.19+$1.96$0.19$1.17B$1.86B        
2/23/2023Q4 2022$4.66$3.61 -$1.05$3.61$5.02B$5.08B          

Moderna Earnings - Frequently Asked Questions

Moderna has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off last year's report dates. Learn more on MRNA's earnings history.

Moderna updated its FY 2025 earnings guidance on Thursday, September, 12th. The company issued revenue guidance of $2.5 billion-$3.5 billion, compared to the consensus revenue estimate of $3.7 billion.

In the previous quarter, Moderna (NASDAQ:MRNA) reported $0.03 earnings per share (EPS) to beat the analysts' consensus estimate of ($1.89) by $1.92. Learn more on analysts' earnings estimate vs. MRNA's actual earnings.

The conference call for Moderna's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Moderna's latest earnings report can be read online.
Read Transcript

Moderna (NASDAQ:MRNA) has a recorded annual revenue of $6.85 billion.

Moderna (NASDAQ:MRNA) has a recorded net income of -$4.71 billion. MRNA has generated -$5.82 earnings per share over the last four quarters.

Moderna's earnings are expected to grow from ($9.43) per share to ($8.69) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:MRNA) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners